Debbie Rigby takes a look at the latest in research news…
This pilot study conducted by one pharmacist in a general practice in Canberra deomstrates the benefits of a general practice pharmacist involved in asthma management. Over 13 months, the pharmacist saw 136 individual patients, with the most common activities being asthma control assessment; recommendations to adjust medication or device; counselling on correct device use; asthma action plan development and trigger avoidance.
This article reviews the international trends in the prevalence of polypharmacy, summarizes the results from previous reviews on polypharmacy and negative health outcomes, and updates a previous review on the clinical consequences of polypharmacy.
Expert Opinion on Drug Safety 2018;17(12):1185-96.
Sacubitril/valsartan is a first-in-class angiotensin receptor-neprilysin inhibitor (ARNI) that has been recommended in clinical practice guidelines to reduce morbidity and mortality in patients with chronic, symptomatic heart failure (HF) with reduced ejection fraction (HFrEF). This review provides an overview of ARNI therapy, proposes strategies to improve the implementation of sacubitril/valsartan in clinical practice, and provides clinicians with evidence-based, practical guidance on the use of sacubitril/valsartan in patients with HFrEF.
Heart Failure Reviews, first online 18 December 2018
This review focuses on medicines approved for the management of insomnia in older people, including suvorexant, low-dose doxepin, Z-drugs (eszopiclone, zolpidem, zaleplon), benzodiazepines (triazolam, temazepam), and ramelteon. The choice of a hypnotic agent in older persons should be symptom-based. Benzodiazepines should not be used routinely.
Drugs & Ageing 2018;35(9):791-817.